Am J Transplant, Volume 18, Suppl 3 Archives - Page 186 of 211 - ATC Abstracts

2018 American Transplant Congress
Metabolic Therapy as a Platform for CTLA4Ig Costimulation Blockade in Preventing Allograft Rejection
C-.H. Cheng,^1,2 C-.F. Lee,^1,2 G. Furtmüller,³ B. Oh,³ C. Patel,¹ Y-.C. Lo,¹ M. Fryer,³ G. Brandacher,³ J. Powell.¹
¹Sidney-Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD; ²Department of Liver and Transplantation Surgery, Chang-Gung Memorial Hospital, New Taipei City, Taiwan; ³Vascularized Composite Allotransplantation Laboratory, Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
The backbone of current immunosuppression regimens remains calcineurin inhibitors (CNI) in association with steroids, mycophenolate mofetil or mTOR inhibitors. However, their long-term administration is associated…
2018 American Transplant Congress
B Cell Immune Repertoire Sequencing Identifies Pre-Transplant Rejection Risk
S. Pineda,^1,2 T. Sigdel,¹ J. Liberto,¹ K. Roskin,³ S. Robin,³ M. Sirota,² M. Sarwal.¹
¹Surgery, UCSF, SF; ²ICHS, UCSF, SF; ³Pathology, Stanford, Stanford.
Background: The diversity of the B cell immune repertoire may drive humoral injury and rejection in organ transplantation (tx).Methods: We utilized advances in next-generation sequencing…
2018 American Transplant Congress
Recipient HO-1 Deficiency Decreases Post-Transplant Graft HO-1 Expression and Exacerbates Liver Transplant Damage
S. Kageyama,¹ K. Nakamura,¹ T. Ito,¹ A. Aziz,¹ B. Ke,¹ R. Sossa,² E. Reed,² F. Kaldas,¹ R. Busuttil,¹ J. Kupiec-Weglinski.¹
¹Surgery, Liver Transplantation, UCLA, Los Angeles, CA; ²Pathology, UCLA, Los Angeles, CA.
Many preclinical studies on protective functions of heme oxygenase-1 (HO-1; hsp32) in orthotopic liver transplantation (OLT) have encouraged application of HO-1 inducing regimens in clinical…
2018 American Transplant Congress
Alemtuzumab is Associated with Higher Rates of De Novo Donor Specific Antibody (DSA) in Patients with No Pre-Transplant DSA
N. Bath, S. Parajuli, G. Leverson, M. Jorgenson, J. Fose, T. Ellis, D. Kaufman, A. Djamali, R. Redfield.
Surgery, University of Wisconsin, Madison, WI.
Introduction: Basiliximab, alemtuzumab, and thymoglobulin are the most commonly used induction agents in the US. While many centers use depleting antibody induction therapy in patients…
2018 American Transplant Congress
Modifiable Causes of Racial Disparities in Living Donor Kidney Transplant
J. Beaumont,¹ J. Peipert,^1,2 C. Anderson,² A. Paiva,³ M. Robbins,³ A. Waterman.^1,2
¹Terasaki Research Institute, Los Angeles, CA; ²Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, CA; ³Department of Psychology, University of Rhode Island, Kingston, RI.
Racial disparities between White and non-White patients in receiving living donor kidney transplants (LDKT) are large and widespread. Yet, the causes of this disparity are…
2018 American Transplant Congress
Retransplantation after Living Donor Liver Transplantation: Analysis of Data from the A2ALL Study
H. Braun, J. Grab, J. Dodge, S. Syed, G. Roll, C. Freise, J. Roberts, N. Ascher.
Surgery, University of California, San Francisco, San Francisco, CA.
Living donor liver transplantation (LDLT) is associated with a higher incidence of post-transplant vascular and biliary complications. Outcomes for retransplantation (reLT) after LDLT are not…
2018 American Transplant Congress
Increasing Use of Exceptions after Changes to Pediatric Heart Allocation
A. Robinson,¹ W. Mahle,² R. Davies.³
¹United Network for Organ Sharing, Richmond, VA; ²Children's Healthcare of Atlanta, Atlanta, GA; ³Children's Medical Center of Dallas, Dallas, TX.
Purpose: Pediatric heart allocation in the United States was changed in 2016. The primary goal was to better align candidate status with waitlist mortality. Whether…
2018 American Transplant Congress
Pre-Existing Renal Cell Carcinomas in Patients with Polycystic Kidney Disease Undergoing Simultaneous Native Nephrectomy and Living Donor Kidney Transplantation
M. Aull,¹ J. Del Pizzo,² A. Watkins,¹ S. Kapur.¹
¹Surgery, Weill Cornell Medical College, New York, NY; ²Urology, Weill Cornell Medical College, New York, NY.
Due to the structural changes to the kidney that occur in polycystic kidney disease (PKD), imaging tests may not pick up pre-transplant renal cancers in…
2018 American Transplant Congress
Long Term Outcomes of Renal Allografts with De Novo DSA in the Setting of Stable Graft Function versus Acute Rejection
R. Knight,¹ D. Nguyen,² E. Graviss,² T. Eagar,² S. Kuten,³ S. Patel,³ L. Moore,¹ A. Gaber.¹
¹Surgery, Houston Methodist Hospital, Houston, TX; ²Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX; ³Pharmacy, Houston Methodist, Houston, TX.
We sought to compare the long-term outcome of renal allograft recipients with de novo DSA (dnDSA) in the setting of stable allograft function versus dnDSA…
2018 American Transplant Congress
Central Role of Mef2 Transcription Factors in Regulation of Foxp3 Expression and Treg Function
A. Samanta,¹ L. Wang,¹ R. Han,¹ W. Hancock.^1,2
¹CHOP, Philadelphia; ²UPenn, Philadelphia.
Foxp3+ Tregs express 4 class IIa Hdac enzymes (Hdac4, 5, 7 & 9) with little or no catalytic activity and yet when deleted, at least…